"zombie" outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York

New England Journal of Medicine

Volumn 376, Issue 3, 2017, Pages 235-242

  Adams, Axel J ^a,b   Banister, Samuel D ^c   Irizarry, Lisandro ^d   Trecki, Jordan ^e   Schwartz, Michael ^f   Gerona, Roy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Wyckoff Heights Medical Center   (United States)

^e Drug Enforcement Administration   (United States)

^f Office of Health Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; METHYL 2 [1 (4 FLUOROBENZYL) 1H INDAZOLE 3 CARBOXAMIDO] 3 METHYLBUTANOATE; UNCLASSIFIED DRUG; INDAZOLE DERIVATIVE; METHYL 2-(1-(4-FLUOROBENZYL)-1H-INDAZOLE-3-CARBOXAMIDO)-3-METHYLBUTANOATE; STREET DRUG; VALINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; EPIDEMIC; HUMAN; INHALATION; INTOXICATION; LETHARGY; LIQUID CHROMATOGRAPHY; MALE; NEW YORK; SWEATING; TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS; ZOMBIE; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; DRUG DEVELOPMENT; MIDDLE AGED; URINE;

ADULT; CANNABINOIDS; DISEASE OUTBREAKS; DRUG DISCOVERY; HUMANS; INDAZOLES; LETHARGY; MALE; MIDDLE AGED; NEW YORK CITY; STREET DRUGS; VALINE;

EID: 85010931096     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1610300     Document Type: Article

References (31)

1. World drug report 2015. Vienna: United Nations Office on Drugs and Crime, 2015.
2. European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances in Europe: an update from the EU Early Warning System. Luxembourg: Publication Office of the European Union, 2016.
3. European Monitoring Centre for Drugs and Drug Addiction. EMCDDA-Europol 2015 annual report on the implementation of Council Decision 2005/387/JHA. Luxembourg: Publications Office of the European Union, 2016.
4. Mechoulam R, Gaoni Y. A total synthesis of dl-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965; 87: 3273-5.
5. Banister SD, Stuart J, Kevin RC, et al. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci 2015; 6: 1445-58.
6. Banister SD, Moir M, Stuart J, et al. Pharmacology of indole and indazole synthetic cannabinoid designer drugs ABFUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADBPINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci 2015; 6: 1546-59.
7. Longworth M, Banister SD, Mack JB, Glass M, Connor M, Kassiou M. The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, ABFUBINACA, AB-PINACA, and 5F-ABPINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicol 2016; 34: 286-303.
8. Banister SD, Longworth M, Kevin R, et al. Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMBFUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci 2016; 7: 1241-54.
9. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44: 832-7.
10. Drug Enforcement Administration. Chemicals used in "spice" and "K2" type products now under federal control and regulation: DEA will study whether to permanently control five substances. March 1, 2011 (https:/ / www .dea .gov/ pubs/ pressrel/ pr030111 .html).
11. Nichols D. Legal highs: the dark side of medicinal chemistry. Nature 2011; 469: 7.
12. Winstock AR, Barrett M, Ferris J, Maier L. Global Drug Survey 2016: what we learned from GDS2016. London: Global Drug Survey, 2016 (https:/ / www .globaldrugsurvey .com/ wp-content/ uploads/ 2016/ 06/ TASTER -KEY-FINDINGS-FROM-GDS2016 .pdf).
13. Auwarter V, Dargan PI, Wood DM. Synthetic cannabinoid receptor agonists. In: Dargan PI and Wood DM, eds. Novel psychoactive substances: classification, pharmacology, and toxicology. London: Elsevier Academic Press, 2013: 317-43.
14. Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012; 120: 238-41.
15. Barratt MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 2013; 32: 141-6.
16. Buser GL, Gerona RR, Horowitz BZ, et al. Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol (Phila) 2014; 52: 664-73.
17. Schwartz MD, Trecki J, Edison LA, Steck AR, Arnold JK, Gerona RR. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med 2015; 48: 573-80.
18. Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 2015; 373: 103-7.
19. Wiley JL, Lefever TW, Marusich JA, et al. Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice. Neuropharmacology 2016; 110: 143-53.
20. Rominger A, Cumming P, Xiong G, et al. Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D2/3 receptor availability: a [18F]fallypride PET study. Eur Neuropsychopharmacol 2013; 23: 1606-10.
21. Buchler IP, Haye MJ, Egde SG, et al., inventors; Pfizer INC., assignee. Indazole derivatives. Intl patent no. PCT/IB2009/ 000432. February 26, 2009.
22. Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y. New cannabimimetic indazole derivatives, N-(1-amino- 3-methyl-1-oxobutan-2-yl)-1-pentyl-1Hindazole- 3-carboxamine (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1- (4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol 2013; 31: 93-100.
23. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: extension of temporary placement of PB-22, 5F-PB-22, ABFUBINACA and ADB-PINACA in Schedule I of the controlled substances act. Final order. Fed Regist 2016; 81: 6175-7.
24. DHH adds two new synthetic marijuana compounds to the banned list. Baton Rouge: Louisiana Department of Health. July 3, 2014 (http://new .dhh .louisiana .gov/ index .cfm/ newsroom/ detail/ 3059).
25. Rosenberg E, Schweber N. 33 Suspected of overdosing on synthetic marijuana in Brooklyn. New York Times. July 12, 2016 (http://www .nytimes .com/ 2016/ 07/ 13/ nyregion/ k2-synthetic-marijuana-overdose -in-brooklyn .html).
26. Holpuch A. More than 30 people fall ill in apparent mass drug overdose in New York. The Guardian. July 13, 2016 (http:// www .theguardian .com/ us-news/ 2016/ jul/ 13/ more-than-30-people-fall-ill-in-apparent -mass-drug-overdose-in-new-york).
27. Akamatsu S, Yoshida M. Fragmentation of synthetic cannabinoids with an isopropyl group or a tert-butyl group ionized by electron impact and electrospray. J Mass Spectrom 2016; 51: 28-32.
28. A look so far into my use of FUBAMB. Reddit research chemicals forum, 2016 (http://www .reddit .com/ r/ research chemicals/ comments/ 4dre6j/ a-look-so-far -into-my-use-of-fubamb/ ).
29. Andersson M, Diao X, Wohlfarth A, Scheidweiler KB, Huestis MA. Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and highresolution mass spectrometry. Rapid Commun Mass Spectrom 2016; 30: 1067-78.
30. Shanks KG, Behonick GS. Death after use of the synthetic cannabinoid 5F-AMB. Forensic Sci Int 2016; 262: e21-4.
31. Tyndall JA, Gerona R, De Portu G, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid ABCHMINACA. Clin Toxicol (Phila) 2015; 53: 950-6.